The mission of Emmaus Life Sciences is to improve the lives of people in need through the discovery, development and commercialization of innovative treatments and therapies. Our focus has been on rare and orphan diseases, such as sickle cell disease. We are now extending our efforts to include conditions and diseases affecting larger populations, such as diverticulosis.
Read MoreSickle cell disease (SCD) is a group of inherited red blood cell disorders that affects about 100,000 Americans. This disease is present in affected individuals at birth and causes the production of abnormal hemoglobin.
Read MoreEmmaus Life Sciences, Inc. today announced a collaboration with the Steve Harvey Morning Show cast member Kier (Junior) Spates to share Mr. Spate’s personal experience with the use of Endari, Emmaus’ prescription L-glutamine oral powder, to treat his sickle cell disease, or SCD.
Read MoreEmmaus Life Sciences, Inc. (OTCQX: EMMA), today reported financial results for the three and six months ended June 30, 2022 and provided a business update.
Read MoreLife Sciences Investor Forum: Company Executives Present Live June 23rd
Read MoreEmmaus Life Sciences, Inc. (OTCQX: EMMA) today reported financial results for the three months ended March 31, 2022 and provided a business update.
Read MoreEmmaus Life Sciences, Inc. today announced participation in the Q2 Investor Summit and the H.C Wainwright Global Investment Conference.
Read MorePlatform Providers Will Handle On-line Prescribing, Dispensing and Delivery of Endari
Read MoreSickle Cell Patients Treated With Endari® had Statistically Significantly Fewer Vaso-Occlusive Events and Hospitalizations Through 72 Weeks Follow-up, Versus Baseline. Adverse Events Among These Patients from French Guiana and Qatar were Few and Mild
Read MoreEmmaus Life Sciences, Inc. today reported financial results for the year ended December 31, 2021 and an update on recent activities.
Read MoreFlorida Joins Other States in Eliminating the Need for Prior Authorization for Medicaid Patients
Read MoreEmmaus Life Sciences, Inc. today announced the approval of its application for marketing authorization of Endari® from the United Arab Emirates (U.A.E.) Ministry of Health after a five-month review of the company’s marketing authorization application.
Read MoreEmmaus Life Sciences, Inc. today announced that real world data on Endari®, the company’s prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, has been accepted for an e-poster at the 62nd Annual Meeting of the British Society for Haematology (BSH) to be held April 3 -5, 2022 at the Manchester Central in Manchester, England and virtually.
Read MoreEmmaus Life Sciences, Inc. today announced that Yutaka Niihara, M.D., M.P.H, Chairman and Chief Executive Officer of Emmaus, will present a company overview at the H.C. Wainwright BioConnect Conference, being held virtually, January 10-13, 2022
Read MoreAnalysis Indicates that Patients Requiring Blood Transfusions and Receiving Endari Required ~43% Fewer Units of Red Blood Cells
Read MoreEmmaus invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com
Read MoreEmmaus Life Sciences, Inc. today announced that data on Endari® has been accepted for a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exhibition.
Read MoreEmmaus Life Sciences, Inc. today reported financial results for the quarter and nine months ended September 30, 2021.
Read MoreEmmaus Life Sciences, Inc. today announced a partnership with UpScript IP Holdings, LLC. (UpScript), to offer telehealth solutions to sickle cell disease patients, expanding access to Endari®, Emmaus’ prescription L-glutamine oral powder for the treatment of sickle cell disease.
Read MoreEmmaus Life Sciences, Inc. today announced it has entered into an agreement with Asembia to provide expanded patient and provider support services in order to simplify access to Endari.
Read MoreEmmaus Life Sciences today announced the submission of its application for marketing authorization of Endari® to the United Arab Emirates (U.A.E.) Ministry of Health.
Read MoreAgreement Expands on the Companies’ Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies
Read MoreOTC Markets Group Inc. (OTCQX: OTCM) today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA) has qualified to trade on the OTCQX® Best Market. Emmaus Life Sciences, Inc. upgraded to OTCQX from the Pink® market.
Read MoreEmmaus Life Sciences, Inc. (OTC: EMMA) announced financial results for the six months ended June 30, 2021. As a result, the company is now current in its Securities and Exchange Commission (SEC) reporting obligations.
Read MoreLicense Permits Importation and Early Access to Patients Pending Marketing Authorization
Read More2020 Financial Statements Restated to Reflect Increase in Net Income Attributable to Change in Equity Method Investment in Japanese Affiliate. Amended and Restated Form 10-K Includes Complete Restated Financial Statements and Currently Dated, Unqualified Audit Report.
Read MoreEmmaus Life Sciences, Inc. (OTC: EMMA) announced today that Endari has been included on the Preferred Drug List published on July 29, 2021, by Texas Health and Human Services (THHS).
Read MoreEmmaus Life Sciences, Inc. announced today preliminary sales results for the six months ended June 30, 2021.
Read MoreEmmaus Life Sciences, Inc. (OTC: EMMA) announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC).
Read MoreEmmaus Life Sciences, Inc announced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus’ application for Marketing Authorization (MA) for Endari® in Switzerland.
Read MoreEmmaus Life Sciences announced today that its application for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia has been accepted by the Saudi Food and Drug Authority (SFDA).
Read MoreEmmaus Life Sciences, Inc. announced today its financial results for the year ended December 31, 2020 as reported in its Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”).
Read MoreEmmaus announced today that its Audit Committee will meet the week of April 19 to review and approve the filing of the company’s 2020 Annual Report on Form 10-K and related earnings release.
Read MoreEmmaus Life Sciences, Inc., announced today that it has entered into an agreement with Kainos Medicine, Inc. (“Kainos”) to lead the preclinical development of Kainos’ patented IRAK4 inhibitor (KM10544) as an anti-cancer drug and further advance the research and development activity currently underway at Kainos.
Read MoreEmmaus Life Sciences, Inc., reports that it sold 25,947 boxes of Endari® in 2020 compared to 24,797 boxes in 2019, an increase of 5%.
Read MoreEmmaus Life Sciences, Inc., reported today its financial results for the year ended December 31, 2019 and its restated financial results for the year ended December 31, 2018.
Read MoreEmmaus Life Sciences, Inc., announced today that it was notified by the Michigan Department of Health and Human Services (MDHHS) that the prior authorization criteria for Endari® was revised after being reviewed by Michigan’s Medicaid Health Plan Common Formulary Workgroup.
Read MoreEmmaus Life Sciences, Inc., announced today the launch of the Endari® Support Program.
Read MoreEmmaus Life Sciences, Inc., announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted orphan drug status to Endari®.
Read MoreEmmaus Life Sciences, Inc., announced today that it has submitted a temporary license application for Endari® to the National Health Regulatory Authority in the Kingdom of Bahrain.
Read MoreEmmaus Life Sciences, Inc., announced today revised prescribing information for Endari® to better inform healthcare professionals and sickle cell disease patients.
Read MoreEmmaus announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities and other business and operations.
Read MoreEmmaus announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia.
Read MoreInterim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue
Read MoreEmmaus provided today additional operational updates for the year ended December 31, 2019 as well as operational updates for the quarters ended March 31 and June 30, 2020
Read MoreEmmaus announced today that the EMA issued scientific advice to Emmaus regarding the clinical development pathway for Xyndari™ for the treatment of sickle cell disease.
Read MoreEmmaus announced today the opening of its regional office in Dubai. The Dubai office will be utilized to enhance Emmaus’ relationships with clinicians and patient groups at major hospitals and other government-sponsored health care facilities in communities throughout the Middle East and North Africa (MENA) region.
Read MoreEmmaus Life Sciences, Inc. is pleased to announce that it has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-glutamine (PGLG) oral powder for use in the treatment of diverticulosis.
Read MoreEmmaus Life Sciences, Inc. announced today that it was issued a license from the Israeli Ministry of Health on June 17, 2020 granting marketing authorization for the commercial distribution and sale of Endari® in Israel.
Read MorePatented Topical Ointment for Treating Skin Ulceration in Sickle Cell Disease and other Indications
Read MoreEmmaus Life Sciences, Inc., provided today operational updates in advance of the filing of its 10-K for the year ended December 31, 2019 and its 10-Q for the first quarter of 2020.
Read MoreEmmaus announced today that APCER Life Sciences (APCER) has confirmed the safety profile of Endari®, Emmaus’ prescription grade L-glutamine oral powder for the treatment of sickle cell disease.
Read MoreEmmaus announced today that the SFDA (Saudi Food & Drug Authority) has accepted its request for priority review of Endari®.
Read MoreWithin the overall SCD community, Emmaus is working in coordination with the Sickle Cell Disease Association of America and other organizations to educate and communicate with the SCD community during this challenging time.
Read MoreEmmaus Life Sciences, Inc., announced today the execution of a purchase agreement for up to $25 million of common stock with Lincoln Park Capital Fund, LLC (“LPC”), a long-only Chicago-based institutional investor.
Read MoreCompany Reports Highest Gross Monthly Sales of 2019 and Total Gross Sales of $7.8 Million in the Fourth Quarter.
Read MoreDecreased Size of Diverticula, Indications of Healing and Normalization of Bowel Movements Observed in the Initial Patient
Read MoreTo the Detriment of the Sickle Cell Disease Community, the Draft Report Does Not Accurately Reflect or Interpret the Original Clinical Data and Related Efficacy and Safety of L-Glutamine Validated and Approved by the FDA
Read MoreImplementing the Program in Collaboration with US Bioservices, an AmerisourceBergen Specialty Pharmacy, Will Drive Increased Compliance with Clinicians Recommended Treatment Programs and Provides an Unprecedented Resource for Patients with Sickle Cell Disease
Read MoreEmmaus Life Sciences, Inc. today reported that it received the initial purchase order relating to taiba Healthcare’s early access program for Endari®.
Read MoreEmmaus Life Sciences, Inc., today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare’s early access program for Endari® (L-glutamine oral powder) in certain countries in the Middle East and North Africa (MENA) region.
Read MoreNet Revenues Increased 25% Year-Over-Year, Company Opens and Expands Class of Trade with Community Hematologists and Correctional Facilities
Read MoreVivozon, Inc. executes a stock purchase agreement for a total of $2.4 million.
Read MoreCompany Reports Highest Gross Sales Month of 2019 and Total Gross Sales of $7.0 Achieved in the Third Quarter.
Read MoreIssuance by the Indian Patent Office Further Bolsters Emmaus’ International Intellectual Property Portfolio
Read MoreEmmaus approved to have its common stock trade on the OTCQB marketplace.
Read MoreSummary review of the clinical trials and efficacy findings for Endari.
Read MoreEmmaus Life Sciences to withdraw MAA
Read MoreCampaign spokesperson Solomon Wilcots will be joined by fellow NFL veteran player Jocelyn Borgella of the Detroit Lions, Dr. Ahmar Zaidi and Dr. Michael Callaghan of the Children’s Hospital of Michigan and the Sickle Cell Disease Association of America Michigan Chapter (SCDAAMI)
Read MoreCompany Committed to Listing on Major Exchange
Read MoreRelated patents granted in the United States, Japan, Australia, Mexico, China, Indonesia, South Korea and Russia; Patents pending in Brazil and other countries
Read MoreEmmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today the addition of Oncology Supply, a part of Amerisource Bergen, as a distributor of its signature product, Endari® (L-glutamine oral powder).
Read MoreCampaign spokesperson Solomon Wilcots will be joined by fellow NFL Veteran Antonio "Dayla" Brown, the Advancing Sickle Cell Advocacy Project (ASAP) and the Foundation for Sickle Cell Disease Research (FSCDR)
Read MoreNet Revenues Increase 128% Year-Over-Year, as FDA-Approved Treatment for Sickle Cell Disease Rolls Out
Read MoreCompany to Announce Second Quarter Financial Results Next Week
Read MoreCompany to Appeal Nasdaq Staff’s Determination
Read MoreCampaign spokesperson Solomon Wilcots and Senior Vice President of Research and Development for Emmaus, Charles Stark, Pharm.D., will lead an informative presentation at the event’s Young Adult Reception.
Read MoreEmmaus to Appeal Nasdaq Staff’s Determination
Read MoreEmmaus Shares Expected to Begin Trading Tomorrow on Nasdaq Under Ticker Symbol “EMMA”
Read MoreThe proposed merger and spin-off transactions were approved by their respective stockholders at the special stockholder meetings held yesterday, July 9, 2019
Read MoreMerger and Spin-off Transaction on Track to Close by End of July New Spin-Off Record Date Set for July 15, 2019
Read MoreStudy will evaluate change in number and size of colonic diverticula and assess safety.
Read MoreEmmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today the hiring of Michael Schwarz as its new Product Manager for Endari®
Read MoreEmmaus to use its pharmaceutical-grade L-glutamine ("PGLG") in a clinical study to determine its efficacy in lowering blood sugar in patients with type II diabetes.
Read MoreEmmaus Life Sciences, Inc., a specialty pharmaceutical and regenerative medicine company, today issued the following statement in response to an announcement issued October 9, 2012, by AFH Holding & Advisory, LLC.
Read MoreTORRANCE, Calif., September 13, 2012 –In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.
Read MoreEmmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission (EC) has granted Orphan Medicinal Product designation for the company’s investigational drug Levoglutamide (L-glutamine) for the treatment of sickle cell disease.
Read MoreEmmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).
Read More